(19)
(11) EP 3 536 687 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
08.09.2021 Bulletin 2021/36

(45) Mention of the grant of the patent:
14.07.2021 Bulletin 2021/28

(21) Application number: 19170210.9

(22) Date of filing: 28.11.2008
(51) International Patent Classification (IPC): 
C07D 239/94(2006.01)
A61K 31/517(2006.01)
A61P 35/00(2006.01)
A61P 19/00(2006.01)
A61P 17/00(2006.01)
 C07D 487/04(2006.01)
A61K 31/519(2006.01)
A61P 35/02(2006.01)
A61P 9/00(2006.01)

(54)

SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE

KLEINMOLEKÜLIGE MYRISTATINHIBITOREN VON BCR-ABL UND VERFAHREN ZUR VERWENDUNG

INHIBITEURS DE MYRISTATE DE BCR-ABL À PETITE MOLÉCULE ET PROCÉDÉS D'UTILISATION

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

(30) Priority: 28.11.2007 US 4462 P

(43) Date of publication of application:
11.09.2019 Bulletin 2019/37

(60) Divisional application:
21184206.7

(62) Application number of the earlier application in accordance with Art. 76 EPC:
16197611.3 / 3150593
08857261.5 / 2222162

(73) Proprietors:
  • Dana-Farber Cancer Institute, Inc.
    Boston, MA 02215 (US)
  • The Scripps Research Institute
    La Jolla, CA 92037 (US)

(72) Inventors:
  • GRAY, Nathanael S.
    Boston, MA 02130 (US)
  • ZHANG, Jianming
    Belmont, MA 02478 (US)
  • OKRAM, Barun
    San Marcos, CA 92078 (US)

(74) Representative: Heller, Benjamin Henry 
Kilburn & Strode LLP Lacon London 84 Theobalds Road
London WC1X 8NL
London WC1X 8NL (GB)


(56) References cited: : 
WO-A1-00/56720
WO-A2-2005/039486
 WO-A2-03/040144
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).